OBJECTIVES: To investigate whether androgen receptor (AR) could serve as a potential molecular target for the treatment of bladder cancer. METHODS: Cell proliferation, apoptosis, and migration capacity were determined in human transitional carcinoma cell lines T24 and 253-J treated with small interfering RNA directed against AR, and expression levels of growth- and metastasis-related genes were assessed using quantitative reverse transcriptase-polymerase chain reaction. Tumor cell growth and apoptosis were also evaluated in vivo in T24 tumor-bearing nude mice receiving electroporation-assisted administration of anti-AR small interfering RNA. RESULTS: AR expression knockdown produced increased apoptosis, decreased proliferation, and migration of bladder cancer cells. Cyclin D1, Bcl-x(L), and matrix metallopeptidase-9 gene expression were also reduced with AR knockdown, which might have contributed to the altered biological behavior of cancer cells. In vivo experiments showed that silencing AR expression, by interference aided by electroporation, significantly suppressed AR-positive bladder tumor growth with decreased cell proliferation and increased apoptotic rates. CONCLUSIONS: Downregulation of AR expression inhibits bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVES: To investigate whether androgen receptor (AR) could serve as a potential molecular target for the treatment of bladder cancer. METHODS: Cell proliferation, apoptosis, and migration capacity were determined in human transitional carcinoma cell lines T24 and 253-J treated with small interfering RNA directed against AR, and expression levels of growth- and metastasis-related genes were assessed using quantitative reverse transcriptase-polymerase chain reaction. Tumor cell growth and apoptosis were also evaluated in vivo in T24 tumor-bearing nude mice receiving electroporation-assisted administration of anti-AR small interfering RNA. RESULTS:AR expression knockdown produced increased apoptosis, decreased proliferation, and migration of bladder cancer cells. Cyclin D1, Bcl-x(L), and matrix metallopeptidase-9 gene expression were also reduced with AR knockdown, which might have contributed to the altered biological behavior of cancer cells. In vivo experiments showed that silencing AR expression, by interference aided by electroporation, significantly suppressed AR-positive bladder tumor growth with decreased cell proliferation and increased apoptotic rates. CONCLUSIONS: Downregulation of AR expression inhibits bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan Journal: Int J Oncol Date: 2011-09-28 Impact factor: 5.650
Authors: Carol A Davis-Dao; Katherine D Henderson; Jane Sullivan-Halley; Huiyan Ma; Dee West; Yong-Bing Xiang; Manuela Gago-Dominguez; Mariana C Stern; J Esteban Castelao; David V Conti; Malcolm C Pike; Leslie Bernstein; Victoria K Cortessis Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-04-14 Impact factor: 4.254
Authors: Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff Journal: Nat Rev Urol Date: 2015-09-22 Impact factor: 14.432
Authors: Patrick Vianna Garcia; Letícia Montanholi Apolinário; Petra Karla Böckelmann; Iseu da Silva Nunes; Nelson Duran; Wagner José Fávaro Journal: Int J Clin Exp Pathol Date: 2015-05-01
Authors: Arshad H Rahmani; Mohammad Alzohairy; Ali Yousif Y Babiker; Amjad A Khan; Salah M Aly; Moshahid A Rizvi Journal: Int J Mol Epidemiol Genet Date: 2013-09-12
Authors: Ming-Wei Chao; Pınar Erkekoglu; Chia-Yi Tseng; Wenjie Ye; Laura J Trudel; Paul L Skipper; Steven R Tannenbaum; Gerald N Wogan Journal: J Appl Toxicol Date: 2014-09-01 Impact factor: 3.446